Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Methyltransferase inhibitors restore SATB1 protective activity against cutaneous T cell lymphoma in mice
Carly M. Harro, Jairo Perez-Sanz, Tara Lee Costich, Kyle K. Payne, Carmen M. Anadon, Ricardo A. Chaurio, Subir Biswas, Gunjan Mandal, Kristen E. Rigolizzo, Kimberly B. Sprenger, Jessica A. Mine, Louise C. Showe, Xiaoqing Yu, Kebin Liu, Paulo C. Rodriguez, Javier Pinilla-Ibarz, Lubomir Sokol, Jose R. Conejo-Garcia
Carly M. Harro, Jairo Perez-Sanz, Tara Lee Costich, Kyle K. Payne, Carmen M. Anadon, Ricardo A. Chaurio, Subir Biswas, Gunjan Mandal, Kristen E. Rigolizzo, Kimberly B. Sprenger, Jessica A. Mine, Louise C. Showe, Xiaoqing Yu, Kebin Liu, Paulo C. Rodriguez, Javier Pinilla-Ibarz, Lubomir Sokol, Jose R. Conejo-Garcia
View: Text | PDF
Research Article Hematology

Methyltransferase inhibitors restore SATB1 protective activity against cutaneous T cell lymphoma in mice

  • Text
  • PDF
Abstract

Cutaneous T cell lymphoma (CTCL) has a poorly understood etiology and no known cure. Using conditional knockout mice, we found that ablation of the genomic organizer special AT-rich sequence–binding protein 1 (Satb1) caused malignant transformation of mature, skin-homing, Notch-activated CD4+ and CD8+ T cells into progressively fatal lymphoma. Mechanistically, Satb1 restrained Stat5 phosphorylation and the expression of skin-homing chemokine receptors in mature T cells. Notably, methyltransferase-dependent epigenetic repression of SATB1 was universally found in human Sézary syndrome, but not in other peripheral T cell malignancies. H3K27 and H3K9 trimethylation occluded the SATB1 promoter in Sézary cells, while inhibition of SUV39H1/2 methyltransferases (unlike EZH2 inhibition) restored protective SATB1 expression and selectively abrogated the growth of primary Sézary cells more effectively than romidepsin. Therefore, inhibition of methyltransferases that silence SATB1 could address an unmet need for patients with mycosis fungoides/Sézary syndrome, a set of incurable diseases.

Authors

Carly M. Harro, Jairo Perez-Sanz, Tara Lee Costich, Kyle K. Payne, Carmen M. Anadon, Ricardo A. Chaurio, Subir Biswas, Gunjan Mandal, Kristen E. Rigolizzo, Kimberly B. Sprenger, Jessica A. Mine, Louise C. Showe, Xiaoqing Yu, Kebin Liu, Paulo C. Rodriguez, Javier Pinilla-Ibarz, Lubomir Sokol, Jose R. Conejo-Garcia

×

Figure 4

Satb1 ablation and Notch activation cooperate to transform postthymic CD4+ T lymphocytes into skin-homing lymphoma cells.

Options: View larger image (or click on image) Download as PowerPoint

Satb1 ablation and Notch activation cooperate to transform postthymic C...
(A) Splenomegaly and adenopathy in a CD4CreERT2Satb1fl/flRosa26N1-ICD mouse 2 months after tamoxifen-mediated activation of transgenes. Representative differences in the size of lymph nodes (LNs) and spleens from different CD4CreERT2Satb1fl/flRosa26N1-ICD mice injected with tamoxifen (n = 9) versus corn oil (vehicle control) (n = 9). (B) Accumulation of CD3+ T cells (red arrows) in the skin of CD4CreERT2Satb1fl/flRosa26N1-ICD mice, 10 weeks after tamoxifen administration. Scale bar: 300 μm. (C) Representative histogram analysis (left) and median fluorescence intensity (MFI, right) of the expression of CCR4 in CD3+CD4+ T cells in the peripheral blood of CD4CreERT2Satb1fl/flRosa26N1-ICD mice, treated with tamoxifen (n = 10) versus corn oil (n = 10). Two-tailed Student’s t test: *P < 0.05. (D) Representative Giemsa staining of peripheral blood in the same mice. Scale bar: 50 μm. A detail of a cerebriform cell is also shown. Scale bar: 10 μm. (E) Expansion of CD4+CD8+CD11b+ T cells in the peripheral blood of CD4CreERT2Satb1fl/flRosa26N1-ICD mice 10 weeks after tamoxifen challenge. (F) Splenomegaly and adenopathy in a CD4CreERT2Satb1fl/flRosa26N1-ICD mouse 2 months after tamoxifen-mediated activation of transgenes. Representative differences in the size of LNs and spleens from different CD4CreERT2Satb1fl/flRosa26N1-ICD versus CD4CreERT2-negative mice. (G) Survival curve of CD4CreERT2Satb1fl/flRosa26N1-ICD mice (n = 12) versus mice without CD4CreERT2 (n = 9). Log-rank (Mantel-Cox) test: *P < 0.05.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts